---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006267"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T23:08:42.998125+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences appoints Kevin Coveney as CFO effective March 13, 2023; interim CFO Robert Dickey IV resigns

## Summary
- Kevin Coveney appointed CFO effective March 13, 2023, succeeding interim CFO Robert Dickey IV.
- Coveney receives $385,000 base salary, bonus up to 40% of base, and 26,500 RSUs vesting over 4 years.
- Coveney brings 30+ years biotech finance experience; previously CFO at Memgen and Q-State Biosciences.
- Interim CFO Robert Dickey IV resigns; resignation not due to any disagreement with company.
- Inducement RSU grant approved by board under NASDAQ Listing Rule 5635(c)(4).

## SEC filing metadata
- accession: 0001493152-23-006267
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/0001493152-23-006267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006267
- JSON: https://secwatch.observer/filing/0001493152-23-006267.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006267.txt

## Key facts
- Executive change
  Kevin M. Coveney was appointed as chief financial officer at Enveric Biosciences, Inc..
  - Action: appointed
  - Role: chief financial officer
  source text: On February 22, 2023, Kevin M. Coveney, 59, was appointed as the chief financial officer of Enveric Biosciences, Inc. (the “Company”) effective March 13, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/0001493152-23-006267-index.htm
- Executive change
  Robert Dickey IV departed as chief financial officer at Enveric Biosciences, Inc..
  - Action: resign
  - Role: chief financial officer
  source text: Effective as of the Effective Date, Robert Dickey IV will resign from his position as the Company’s chief financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/0001493152-23-006267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.